Clinical trial · Observational
Amino Acid Transporter System PET/CT Imaging in AATS-Related Diseases
NCT07379463CI-TRIAL-00102070recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 9, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260909-000002
Summary
Brief summary (as posted)
To evaluate the potential usefulness of 11C/18F-MET/FET positron emission tomography/ computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various amino acid transporter system (AATS)-related disease patients.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Amino-Acid Transport Disorder | — | UNRESOLVED | — |
| Glioma | Glioma | ONTOLOGY_EXACT | 0.98 |
| Primary Hyperparathyroidism | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 11C/18F-MET/FET | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Single Group Assignment
- description
- Each subject receive a single intravenous injection of 11C/18F-MET/FET, and undergo PET/CT imaging within the specificed time.
- interventionNames
- Diagnostic Test: 11C/18F-MET/FET
Primary outcomes (1)
- measure
- Standardized uptake value (SUV)
- timeFrame
- 30 days
- description
- Standardized uptake value (SUV) of AATS for each target lesion of subject or suspected primary tumor or/and metastasis.
Secondary outcomes (1)
- measure
- Diagnostic efficacy
- timeFrame
- 30 days
- description
- The sensitivity, specificity and accuracy of AATS PET/CT were calculated.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: 1. adult patients (aged 18 years or order); 2. patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); 3. patients who had scheduled AATS PET/CT scan; 4. patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: 1. patients with non-malignant lesions; 2. patients with pregnancy; 3. the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
References
Publications (0)
Data not yet available
No reference posted for this study.